The clinical value of aquaporin-4 in children with hand, foot, and mouth disease and the effect of magnesium sulfate on its expression: a prospective randomized clinical trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Children with HFMD were divided into a common group, a severe group and a critical group according to Chinese guidelines; children in the critical group were further divided into two subgroups: routine treatment group and MgSO4 group.

Outcome measures included systolic blood pressure (SBP), Heart rate (HR), the levels of AQP-4, interleukin-6 (IL-6), norepinephrine (NE), and neuron-specific enolase (NSE).

Who Took Part

PubMed indexes the participants as infants and young children, both men and women.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

What Was Measured

Outcome measures included systolic blood pressure (SBP), Heart rate (HR), the levels of AQP-4, interleukin-6 (IL-6), norepinephrine (NE), and neuron-specific enolase (NSE).

The subject headings attached to it are Aquaporin 4, Biomarkers, Hand, Foot and Mouth Disease, Interleukin-6, Magnesium Sulfate, Norepinephrine and Phosphopyruvate Hydratase.

Author keywords: Aquaporin-4, Cerebral injury and Hand, foot, and mouth disease.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2019 (European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.